Improvements in patient-reported outcomes after treatment with deucravacitinib in patients with psoriatic arthritis: Results from a randomized Phase 2 trial

Arthritis Care Res (Hoboken). 2024 Mar 26 doi: 10.1002/acr.25333 Epub ahead of print

Deucravacitinib improved physical and social functioning, mental health, fatigue, and pain in a
Phase 2 trial in patients with active PsA. Here, investigators aimed to report the impact of deucravacitinib in a Phase 2 study in patients with active PsA from a patient perspective.

The reported data suggest that deucravacitinib is a promising therapeutic option for improving HRQoL and other PROs in patients with PsA.

Keywords:


Publication thumbnail: Improvements in patient-reported outcomes after treatment with deucravacitinib in patients with psoriatic arthritis: Results from a randomized Phase 2 trial
LinkedIn